Articles from MedaSystems

MedaSystems, the leading SaaS platform for Expanded Access, Post Trial Access, and Investigator Initiated Studies, today announced a milestone year defined by accelerated customer growth, strong clinical adoption, and significant advances in regulatory and AI readiness. The company continued to expand its role as a trusted partner to life sciences organizations and clinicians seeking treatment pathways for patients with urgent medical needs.

MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator‑Initiated Studies (IIS), today announced that healthcare‑technology veteran Anton White has joined the company as Vice President of Growth. White will lead global go‑to‑market strategy and execution as MedaSystems scales to meet accelerating demand from biopharmaceutical partners worldwide.

MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS), today announced a significant new product release that aims to improve and automate the user experience of life sciences companies when receiving, processing, and acting on requests from physicians for expanded and managed access use cases. These new product enhancements will offer a seamless and secure process for accelerating approval decisions, reducing repetitive manual work, and collaborating with health care providers.

MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS), today announced additional funding from existing investors, Debiopharm Innovation Fund, Nina Capital, and Young Sohn, a co-founder of Veeva Systems. This investment underscores confidence in MedaSystems’ ability to modernize pre-approval access pathways through its AI-driven workflow platform. By streamlining Expanded Access and IIS workflows, MedaSystems helps pharmaceutical companies and healthcare providers efficiently manage requests, improve patient access, and capture real-world data (RWD) to support evidence generation and regulatory submissions.

MedaSystems, the leading SaaS platform for Expanded Access and Investigator Initiated Trials, is pleased to announce the recent appointment of Brian Irwin as Chief Executive Officer and Board Member. With over 25 years of strategic leadership in Life Science data analytics, SaaS technology, and healthcare investing, Brian joins MedaSystems at a pivotal time, bringing an impressive track record in scaling growth within these sectors.

MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner. The investment adds to a growing list of prominent digital health investors in Europe and the United States, including Nina Capital and Young Sohn, a co-founder of Veeva Systems. The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.

MedaSystems, developer of the only purpose-built pharma-physician network to provide patients with access to pre-approval medicine*, today announced the completion of a seed funding round. Participants in the round include a mix of strategic angel and health tech venture investors, with prior track records of founding and funding successful SaaS health companies, including Young Sohn, a founder of Veeva Systems, Vlocity, and Nomadic Systems; nina.capital, a specialist healthtech venture capital fund based in Barcelona; and members of the management team.